Search results for "Nipecotic Acids"

showing 9 items of 9 documents

Free-choice ethanol consumption under the influence of GABAergic drugs in rats.

2002

Background: Neurobiological mechanisms leading from controlled alcohol consumption to addiction are poorly understood. Among multiple neurotransmitters γ-amino-butyric acid (GABA) is suggested to play a role. The present investigation studied effects of drugs interacting with the GABAergic system on the motivation of ethanol consumption. Methods: Fifty male PVG/OlaHsd rats were analyzed for free-choice ethanol drinking behavior without and with pre-exposure to drugs acting on the GABAergic system. For pretreatment, animals received the benzodiazepine agonists or antagonists diazepam, flumazenil, or Ro15-4513, or the GABA uptake inhibitor tiagabine via the drinking water for 4 weeks (day −21…

MaleTiagabineAlcohol Drinkingmedicine.drug_classNipecotic AcidsMedicine (miscellaneous)Administration OralPharmacologyToxicologyChoice BehaviorGABA Antagonistschemistry.chemical_compoundReceptors GABAmedicineGABA transporterAnimalsTiagabineGABA AgonistsBenzodiazepineEthanolbiologybusiness.industryRatsPsychiatry and Mental healthchemistryFlumazenilbiology.proteinGABAergicReuptake inhibitorbusinessDiazepammedicine.drugAlcoholism, clinical and experimental research
researchProduct

Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma

2014

Systemic sclerosis (SSc), or scleroderma, similar to many fibrotic disorders, lacks effective therapies. Current trials focus on anti-inflammatory drugs or targeted approaches aimed at one of the many receptor mechanisms initiating fibrosis. In light of evidence that a myocardin-related transcription factor (MRTF)–and serum response factor (SRF)–regulated gene transcriptional program induced by Rho GTPases is essential for myofibroblast activation, we explored the hypothesis that inhibitors of this pathway may represent novel antifibrotics. MRTF/SRF-regulated genes show spontaneously increased expression in primary dermal fibroblasts from patients with diffuse cutaneous SSc. A novel small-m…

MaleSerum Response Factormedicine.medical_specialtyOncogene Proteins FusionTranscription GeneticNipecotic AcidsDiseaseSclerodermaDrug Discovery and Translational MedicineInternal medicinemedicineAnimalsHumansMyofibroblastsskin and connective tissue diseasesPharmacologyScleroderma Systemicintegumentary systembusiness.industrymedicine.diseaseConnective tissue diseaseDermatologyRheumatologyDNA-Binding Proteinsstomatognathic diseasesMolecular MedicineFemalebusinessJournal of Pharmacology and Experimental Therapeutics
researchProduct

Tiagabine, a gamma-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze.

2002

Abstract γ-Amino-butyric acid (GABA) is cleaved from the synaptic cleft by uptake via specific transporters. Inhibition of such transporters increases the effectiveness of physiologically released GABA. Increased GABAergic neurotransmission has an impact on learning and memory. Therefore, effects of tiagabine, a GABA-transporter inhibitor, were investigated on spatial orientation in the Morris water-maze. Rats were given four training trials per day for 4 days and a probe trial without platform on the 5th day. Compared to saline treated rats, rats treated daily with 20 mg/kg tiagabine showed impaired learning during the acquisition trials. Retrieval was impaired in rats treated only at the …

MaleGABA Plasma Membrane Transport ProteinsSynaptic cleftTiagabinemedicine.medical_treatmentNipecotic AcidsMorris water navigation taskOrganic Anion TransportersPharmacologyBehavioral Neurosciencechemistry.chemical_compoundMemorymedicineGABA transporterAnimalsNeurotransmitterMaze LearningTiagabineSalineGABA AgonistsSwimmingbiologyMembrane ProteinsMembrane Transport ProteinsTransporterRats Inbred StrainsReceptors GABA-ARatschemistrybiology.proteinReuptake inhibitorCarrier ProteinsNeurosciencemedicine.drugBehavioural brain research
researchProduct

Non-convulsive status epilepticus associated with tiagabine in a pediatric patient

2003

We report a 4-year-old patient who developed non-convulsive status epilepticus (NCSE) following tiagabine (TGB) as add-on treatment for refractory partial seizures. NCSE occurred while the patient received TGB 0.83mg/kg/day. In our case, the TGB reduction led to a significant improvement of electroclinical features. The mechanisms of this abnormal effect are not clear. GABA-ergic hyperfunction and/or multiplicity of interlinked brain GABA systems associated with individual specific sensitivity could play a critical role in the pathogenesis of NCSE. This is the first report of NCSE documented by electroencephalogram (EEG) in a child under 12 years of age on TGB treatment. © 2003 Elsevier Sci…

MaleTiagabinemedicine.medical_treatmentNipecotic AcidsStatus epilepticusNon-convulsive status epilepticuElectroencephalographyCentral nervous system diseaseEpilepsyStatus EpilepticusDevelopmental NeuroscienceRefractorymedicineHumansTiagabineEpilepsymedicine.diagnostic_testbusiness.industryElectroencephalographyGeneral Medicinemedicine.diseaseAnticonvulsantnervous systemEl NiñoChild PreschoolAnesthesiaPediatrics Perinatology and Child HealthAnticonvulsantsEpilepsies PartialNeurology (clinical)medicine.symptombusinessmedicine.drugBrain and Development
researchProduct

Intracellular Na+ concentration influences short-term plasticity of glutamate transporter-mediated currents in neocortical astrocytes.

2012

Fast synaptic transmission requires a rapid clearance of the released neurotransmitter from the extracellular space. Glial glutamate transporters (excitatory amino acid transporters, EAATs) strongly contribute to glutamate removal. In this work, we investigated the paired-pulse plasticity of synaptically activated, glutamate transporter-mediated currents (STCs) in cortical layer 2/3 astrocytes. STCs were elicited by local electrical stimulation in layer 4 in the presence of ionotropic glutamate (AMPA and NMDA), GABAA, and GABAB receptor antagonists. In experiments with low [Na+]i (5 mM) intrapipette solution, STCs elicited by paired-pulse stimulation demonstrated paired-pulse facilitation (…

Intracellular FluidPatch-Clamp TechniquesAmino Acid Transport System X-AGBiophysicsNipecotic AcidsAction PotentialsNeocortexAMPA receptorTetrodotoxinBiologyGABAB receptorAnisolesIn Vitro TechniquesSynaptic TransmissionGABA AntagonistsCellular and Molecular NeuroscienceMiceCadmium ChlorideEthers CyclicOximesmedicineGABA transporterAnimalsgamma-Aminobutyric AcidBenzofuransAspartic AcidNeuronal PlasticityGABAA receptorRhodaminesSodiumGlutamate receptorCalcium Channel BlockersElectric StimulationMice Inbred C57BLmedicine.anatomical_structureNeurologyAnimals NewbornAstrocytesExcitatory postsynaptic potentialBiophysicsbiology.proteinNMDA receptorNeuroscienceExcitatory Amino Acid AntagonistsAstrocyteSodium Channel BlockersGlia
researchProduct

Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.

2002

Acute GABA transporter inhibition can induce anxiolytic-like behaviors. The present analysis addressed whether chronic treatment (23 days via drinking water) with a GABA transporter inhibitor affects rat behavior similar to acute treatment and interferes with additional benzodiazepine-receptor agonistic treatment. Seventy-one rats divided into seven groups were acutely treated with either vehicle, diazepam (2 mg/kg), zolpidem (0.05 mg/kg), tiagabine (19 mg/kg) or chronically with tiagabine with or without acute diazepam or zolpidem. Animals were behaviorally characterized in an elevated plus-maze. None of the treatments induced changes in the activity of the animals. Acute and chronic treat…

AgonistMalemedicine.medical_specialtyElevated plus mazeZolpidemGABA Plasma Membrane Transport ProteinsTime FactorsTiagabinemedicine.drug_classPyridinesNipecotic AcidsOrganic Anion TransportersPharmacologyAnxiolyticDrug Administration Schedulechemistry.chemical_compoundInternal medicinemedicineGABA transporterAnimalsNeurotransmitterMaze LearningTiagabineBiological PsychiatryDiazepambiologyBehavior Animalbusiness.industryMembrane ProteinsMembrane Transport ProteinsDrug SynergismRats Inbred StrainsRatsZolpidemPsychiatry and Mental healthEndocrinologyNeurologychemistryAnti-Anxiety Agentsbiology.proteinNeurology (clinical)businessCarrier ProteinsDiazepammedicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

Behavioral Effects of GABAA Receptor Stimulation and GABA-Transporter Inhibition

2000

Abstract The present analysis addressed behavioral changes after treatment with 4.5 mg/kg or 18.5 mg/kg of the GABA-uptake inhibitor tiagabine combined with either the benzodiazepine diazepam (1.5 mg/kg) or the imidazopyridine zolpidem (0.05 mg/kg), the latter two acting differentially on GABA A receptor subtypes. The study included 97 male PVG/OIaHsd rats. A standard open field, an enriched open field, and an elevated plus-maze was used to study rat behavior. Treatment with the low dose of tiagabine alone induced no specific behavioral effects, whereas the high dose had an anxiolytic-like potential. Furthermore, diazepam but not zolpidem displayed anxiolytic-like effects. Combination of ea…

MaleAgonistGABA Plasma Membrane Transport Proteinsmedicine.medical_specialtyZolpidemTiagabinePyridinesmedicine.drug_classmedicine.medical_treatmentClinical BiochemistryNipecotic AcidsOrganic Anion TransportersMotor ActivityPharmacologyToxicologyBiochemistryOpen fieldBehavioral NeuroscienceInternal medicinemedicineAnimalsHypnotics and SedativesDrug InteractionsNeurotransmitter Uptake InhibitorsTiagabineBiological PsychiatryPharmacologyBenzodiazepineBehavior AnimalChemistryGABAA receptorMembrane ProteinsMembrane Transport ProteinsReceptors GABA-ARatsZolpidemEndocrinologyAnticonvulsantDrug Therapy CombinationCarrier ProteinsDiazepammedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze.

1999

The behavioural consequences of inhibition of gamma-aminobutyric acid (GABA) uptake were studied. Two GABA uptake inhibitors, tiagabine and SKF 89976-A, were administered to rats, and behaviour was analysed 30 min later in a standard open field, an enriched open field, and an elevated plus-maze. Eight groups of animals received either saline (0.9%), tiagabine, or SKF 89976-A. At a dose of 18.5 mg/kg, tiagabine, an established antiseizure drug, impaired motor coordination, enhanced exploratory activity and reduced anxiety related behaviour. SKF 89976-A exhibited minimal effects over the dose range tested. These results indicate that inhibition of GABA uptake might be a pharmacological strate…

GABA Plasma Membrane Transport ProteinsMaleElevated plus mazeGABA Plasma Membrane Transport ProteinsTiagabineGABA AgentsNipecotic AcidsOrganic Anion TransportersPharmacologyAnxietyEnvironmentMotor Activitygamma-Aminobutyric acidOpen fieldmedicineGABA transporterAnimalsTiagabineGABA Agonistsgamma-Aminobutyric AcidPharmacologybiologyBehavior AnimalDose-Response Relationship DrugChemistryMembrane ProteinsMembrane Transport ProteinsRatsPsychiatry and Mental healthGABA Agentsnervous systembiology.proteinExploratory BehaviorGABA Uptake InhibitorsAnticonvulsantsCarrier Proteinsmedicine.drugBehavioural pharmacology
researchProduct

Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABA(A)-receptor.

2001

Abstract 1. GABA A -receptor induced changes in locomotion and anxiety-like behaviors were studied in rats using an open-field and an elevated plus-maze. Acute and chronic doses of the benzodiazepine diazepam without and in combination with the GABA uptake inhibitor SKF-89976A were investigated. 2. Fifty-six male rats of the strain PVG/OlaHsd (PVG; 180–200g body wt) were used to assess the influence of the benzodiazepine binding-site to the development of tolerance. Rats were divided into six groups: The first receiving saline (0.9%), the second and third diazepam (10.0 mg/kg) daily for 23 days with or without an acute challenge of 2.0 mg/kg diazepam. The fourth group received diazepam (10.…

MaleElevated plus mazemedicine.medical_specialtymedicine.drug_classGABA AgentsNipecotic AcidsOpen fieldchemistry.chemical_compoundOral administrationInternal medicineMedicineAnimalsheterocyclic compoundsMaze LearningBiological PsychiatryPharmacologyBenzodiazepineDiazepamGABAA receptorbusiness.industryReceptors GABA-ARatsEndocrinologychemistryAnti-Anxiety AgentsExploratory BehaviorSKF-89976AbusinessReuptake inhibitorDiazepammedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct